Group 1 - The initial transfer price determined for the share transfer is 6.57 CNY per share based on the inquiry from institutional investors on August 22, 2025 [1][2] - The transfer process will include an additional subscription procedure, with the deadline for additional subscriptions no later than September 4, 2025 [1] - The share transfer does not involve any change in the company's control and will not affect the company's governance structure or ongoing operations [2]

一、本次询价转让初步定价 证券代码：688373 证券简称：盟科药业 公告编号：2025-034 上海盟科药业股份有限公司 股东询价转让定价情况提示性公告 JSR Limited 和 Best Idea International Limited（以下合称"出让方"）保证向 上海盟科药业股份有限公司（以下简称"公司"）提供的信息内容不存在任何虚 假记载、误导性陈述或者重大遗漏，并对其真实性、准确性和完整性依法承担法 律责任。 公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 根据 2025 年 8 月 22 日询价申购情况，初步确定的本次询价转让价格为 6.57 元/股。 （一）经向机构投资者询价后，初步确定的转让价格为 6.57 元/股。 （二）经出让方与组织券商协商，一致决定启动追加认购程序，追加认购截 止时间不晚于 2025 年 9 月 4 日。 二、风险提示 （一）本次询价转让受让方及受让股数仅为初步结果，尚存在拟转让股份被 司法冻结、扣划等风险。询价转让的最终结果以中国证券登记结算有限责任公司 上海分公司最终办理结果为准。 （二）本次询价转让不涉及公司控制权变更，不会 ...

Core Viewpoint - The company Mengke Pharmaceutical (688373.SH) has announced a share transfer plan involving major shareholders JSR Limited and Best Idea International Limited, with a total of 22,946,192 shares to be transferred, representing 3.50% of the company's total equity [1] Group 1: Share Transfer Details - The share transfer is a non-public transfer and will not occur through centralized bidding or block trading, thus not classified as a secondary market reduction [1] - The transferees must be institutional investors with appropriate pricing capabilities and risk tolerance [1] - The shares acquired through this transfer cannot be sold within six months after the transfer [1] Group 2: Shareholder Information - JSR Limited and Best Idea International Limited are the third and fourth largest shareholders of Mengke Pharmaceutical, respectively [1] - The top ten shareholders include Genie Pharma (10.92%), MicuRx (HK) Limited (10.79%), Best Idea International Limited (10.49%), and JSR Limited (5.88%) [2] Group 3: Financial Performance - Mengke Pharmaceutical has been publicly listed on the Shanghai Stock Exchange since August 5, 2022, with an initial public offering (IPO) price of 8.16 yuan per share [3] - The company has reported continuous losses for three and a half years, with revenues of 48.21 million yuan, 90.77 million yuan, and 130 million yuan from 2022 to 2024, and net losses of 220 million yuan, 421 million yuan, and 441 million yuan during the same period [4] - In the first half of 2025, the company reported a revenue of 66.97 million yuan, a year-on-year increase of 10.26%, but still a net loss of 139 million yuan [4]

Group 1 - The core viewpoint of the article is that China International Capital Corporation (CICC) has conducted a qualification review for the shareholders of Shanghai Mengke Pharmaceutical Co., Ltd. regarding their inquiry for share transfer to specific institutional investors [1][5] - CICC received a commission from the shareholders JSR Limited and Best Idea International Limited to organize the inquiry transfer [1] - The review process included verifying the registration certificates and compliance with relevant regulations for both JSR and Best Idea [2][4] Group 2 - JSR Limited was established on March 11, 2015, in the British Virgin Islands, and its main business is equity investment [2][3] - JSR has not violated any regulations regarding share reduction and is not a controlling shareholder of Mengke Pharmaceutical [3] - Best Idea International Limited was established on July 22, 2010, in Hong Kong, and its main business is also equity investment [4] - Best Idea has similarly complied with share reduction regulations and is not a controlling shareholder of Mengke Pharmaceutical [4][5] Group 3 - CICC concluded that both JSR and Best Idea meet the necessary qualifications for participating in the share inquiry transfer, with no violations of relevant regulations identified [5]

Buyback and Shareholder Actions - Sinopec plans to repurchase A-shares with a total fund of no less than RMB 5 billion and no more than RMB 10 billion, potentially reducing its registered capital [1] - Hengbang Mining intends to reduce its stake in the Hong Kong-listed company, WanGuo Gold, by up to 40 million shares, representing approximately 3.69% of WanGuo's total share capital [5] Product Approvals and Market Launches - Wantai Biological's nine-valent HPV vaccine has received the batch release certificate, marking its official market launch and enhancing the company's product lineup [1] - Changchun High-tech's subsidiary has received acceptance for the clinical trial application of GenSci143, a dual-specific antibody drug, which may provide new treatment options for certain tumors [7] Financial Performance - Hongxin Electronics reported a 15.01% increase in revenue to RMB 3.494 billion and a 9.85% rise in net profit to RMB 53.99 million for the first half of 2025 [2] - Sanwei Xinan experienced a net loss of RMB 29.39 million in the first half of 2025, despite a 15.19% increase in revenue to RMB 195 million [3] Corporate Developments - TianTan Bio received a commitment from its controlling shareholder to resolve new competition issues arising from a recent acquisition [4] - Feilu Co. announced a potential change in control, leading to a temporary suspension of its stock trading [8] Investment and Expansion - Jinbei Electric's subsidiary has signed a purchase agreement for a factory in Europe, marking significant progress in establishing its European production base [1] - Shengshi Technology plans to establish a wholly-owned subsidiary to integrate AI and humanoid robot technology with innovative toy products, investing RMB 10 million [6]

Company Announcements - Dameng Data's board member and senior vice president is under investigation by the Hubei Provincial Supervisory Committee, but the company's operations remain normal [1] - Jishi Media reported a net loss of 232 million yuan in the first half of 2025, despite a revenue increase of 8.7% to 999.7 million yuan [2] - Wantai Biological's nine-valent HPV vaccine has received its first batch release certificate, marking its market entry and potential revenue growth [2] - Feilu Co., Ltd. is undergoing a change in control, leading to a suspension of its stock trading starting August 22 [2] Financial Performance - Sany Heavy Industry reported a 46% increase in net profit to 5.216 billion yuan in the first half of 2025, with a revenue of 44.534 billion yuan, up 14.96% [3] - EVE Energy's net profit decreased by 24.9% to 1.605 billion yuan, despite a revenue increase of 30.06% to 28.169 billion yuan [5] - GoerTek achieved a net profit increase of 15.65% to 1.42 billion yuan, with a revenue of 37.55 billion yuan, down 7.02% [6] Approvals and Projects - Changchun High-tech's subsidiary received acceptance for a clinical trial application for GenSci143, a dual-specificity antibody drug targeting B7-H3 and PSMA [7] - Zejing Pharmaceutical received approval for clinical trials of ZG005 and ZGGS18 in combination with a specific cancer drug [7] Financing and Capital Increase - Zhenghe Industrial plans to raise no more than 818 million yuan through a private placement for various projects and working capital [8] Shareholding Changes - Zhongyin Securities announced that Jiangxi Copper plans to reduce its stake by up to 3%, equating to 83.34 million shares [9] - Mengke Pharmaceutical's shareholders plan to transfer 22.946 million shares, representing 3.5% of the total share capital [15] Investments and Strategic Partnerships - Diou Home plans to establish a wholly-owned subsidiary with an investment of 500 million yuan to expand into the generative AI field [11] - Gree Green signed a strategic cooperation agreement with Weilan Lithium to develop ultra-high energy density battery materials and solid-state battery innovations [12]

中国国际金融股份有限公司 关于上海盟科药业股份有限公司股东向特定机构投资者询价转让股份 相关资格的核查意见 （二）核查情况 1、JSR Limited 中国国际金融股份有限公司（以下简称"中金公司"）受上海盟科药业股份有限公 司（以下简称"盟科药业"）股东 JSR Limited 和 Best Idea International Limited（以下 分别简称"JSR"和"Best Idea"，合称"出让方"）委托，组织实施本次盟科药业股东 向特定机构投资者询价转让（以下简称"本次询价转让"）。 根据《关于在上海证券交易所设立科创板并试点注册制的实施意见》《科创板上市 公司持续监管办法（试行）》《上海证券交易所科创板股票上市规则》《上海证券交易所 科创板上市公司自律监管指引第 4 号——询价转让和配售》（以下简称"《询价转让和 配售指引》"）等相关规定，中金公司对参与本次询价出让方的相关资格进行了核查。 本次询价转让的委托情况、出让方相关资格的核查情况及核查意见如下： 一、本次询价转让的委托 中金公司已收到出让方关于本次询价转让的委托，委托中金公司组织实施本次询 价转让。 二、关于参与本次询价转让股东相关资 ...

证券代码：688373 证券简称：盟科药业 公告编号：2025-033 上海盟科药业股份有限公司 股东询价转让计划书 JSR Limited 和 Best Idea International Limited（以下分别简称"JSR"和"Best Idea"，合称"出让方"）保证向上海盟科药业股份有限公司（以下简称"公司" "盟科药业"）提供的信息内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其真实性、准确性和完整性依法承担法律责任。 | 序号 | 股东名称 | | 持股数量（股） | | 持股占总股本比例 | | --- | --- | --- | --- | --- | --- | | 1 | JSR | 注 | | 38,579,770 | 5.88% | | 2 | Best Idea | | | 68,752,718 | 10.49% | 注：该股东一致行动人 GP TMT Holdings Limited 持有公司 2.80%股份 1 拟参与盟科药业首发前股东询价转让（以下简称"本次询价转让"）的股东 为 JSR Limited 和 Best Idea International Limit ...

每经AI快讯，8月21日，盟科药业(688373.SH)公告称，股东JSR Limited和Best Idea International Limited 计划通过询价转让方式，转让其持有的公司22,946,192股股份，占公司总股本的3.50%。转让原因为股 东自身资金需求。 ...

据证券之星公开数据整理，近期盟科药业(688373)发布2025年中报。截至本报告期末，公司营业总收入 6696.98万元，同比上升10.26%，归母净利润-1.39亿元，同比上升31.11%。按单季度数据看，第二季度 营业总收入3375.28万元，同比上升21.75%，第二季度归母净利润-7704.2万元，同比上升22.31%。本报 告期盟科药业盈利能力上升，毛利率同比增幅4.02%，净利率同比增幅37.52%。 本次财报公布的各项数据指标表现尚佳。其中，毛利率84.79%，同比增4.02%，净利率-207.07%，同比 增37.52%，销售费用、管理费用、财务费用总计8296.5万元，三费占营收比123.88%，同比减16.45%， 每股净资产0.48元，同比减52.16%，每股经营性现金流-0.18元，同比增47.33%，每股收益-0.21元，同 比增32.26% | 项目 | 2024年中报 | 2025年中报 | 同比增幅 | | --- | --- | --- | --- | | 营业总收入(元) | 6073.82万 | 6696.98万 | 10.26% | | 归母浄利润（元） | -2.0 ...